Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice
- 30 October 2003
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 58 (2), 145-155
- https://doi.org/10.1002/pros.10281
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- PSMA specific antibodies and their diagnostic and therapeutic useExpert Opinion on Investigational Drugs, 2001
- Efficacy and toxicity of radioimmunotherapy with90Y-DOTA-peptide-ChL6 for PC3-tumored miceThe Prostate, 2000
- Monoclonal antibodies: will they become an integral part of the evaluation and treatment of prostate cancer - focus on prostate-specific membrane antigen?Current Opinion in Urology, 1999
- Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinomaCancer, 1998
- Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenograftsProceedings of the National Academy of Sciences of the United States of America, 1997
- Upregulation of prostate-specific membrane antigen after androgen-deprivation therapyUrology, 1996
- Localization and Physical Mapping of the Prostate-Specific Membrane Antigen (PSM) Gene to Human Chromosome 11Genomics, 1995
- Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluidsInternational Journal of Cancer, 1995
- Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigenUrologic Oncology, 1995
- Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissuesUrologic Oncology, 1995